The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

被引：30

作者：

Belani, Chandra P. ^{[1
]}

机构：

[1] Penn State Milton S Hershey Med Ctr, Penn State Hershey Canc Inst, Hershey, PA 17033 USA

来源：

CANCER INVESTIGATION | 2010年 / 28卷 / 04期

关键词：

Non-small cell lung cancer; Epidermal growth factor receptor; HER2; Irreversible tyrosine kinase inhibitors-BIBW 2992; HKI-272; PF00299804; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; I DOSE-ESCALATION; PREVIOUSLY TREATED PATIENTS; PAN-ERBB INHIBITOR; ACQUIRED-RESISTANCE; PHASE-I; EGFR/HER2; INHIBITOR; CLINICAL ACTIVITY; T790M MUTATIONS;

D O I：

10.3109/07357901003631072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Reversible epidermal growth factor receptor tyrosine kinase inhibitors are often used for the treatment of non-small cell lung cancer following failure of cytotoxic chemotherapy. While these agents are active in a subset of patients, most develop resistance and progress within the course of 1 year. In nearly half of the cases, acquired resistance is caused by a secondary epidermal growth factor receptor T790M mutation. Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance.

引用

页码：413 / 423

页数：11

共 84 条

[21] A RANDOMIZED TRIAL OF INDUCTION CHEMOTHERAPY PLUS HIGH-DOSE RADIATION VERSUS RADIATION ALONE IN STAGE-III NON-SMALL-CELL LUNG-CANCER [J].

DILLMAN, RO ;

SEAGREN, SL ;

PROPERT, KJ ;

GUERRA, J ;

EATON, WL ;

PERRY, MC ;

CAREY, RW ;

FREI, EF ;

GREEN, MR .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :940-945

[22] Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) [J].

Elkind, NB ;

Szentpétery, Z ;

Apáti, A ;

Özvegy-Laczka, C ;

Várady, G ;

Ujhelly, O ;

Szabó, K ;

Homolya, L ;

Váradi, A ;

Buday, L ;

Kéri, G ;

Német, K ;

Sarkadi, B .

CANCER RESEARCH, 2005, 65 (05) :1770-1777

[23] PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Gale, Christopher-Michael ;

Lifshits, Eugene ;

Gonzales, Andrea J. ;

Shimamura, Takeshi ;

Zhao, Feng ;

Vincent, Patrick W. ;

Naumov, George N. ;

Bradner, James E. ;

Althaus, Irene W. ;

Gandhi, Leena ;

Shapiro, Geoffrey I. ;

Nelson, James M. ;

Heymach, John V. ;

Meyerson, Matthew ;

Wong, Kwok-Kin ;

Janne, Pasi A. .

CANCER RESEARCH, 2007, 67 (24) :11924-11932

[24] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[25] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [J].

Eskens, Falm ;

Mom, C. H. ;

Planting, A. S. T. ;

Gietema, J. A. ;

Amelsberg, A. ;

Huisman, H. ;

van Doorn, L. ;

Burger, H. ;

Stopfer, P. ;

Verweij, J. ;

de Vries, Ege .

BRITISH JOURNAL OF CANCER, 2008, 98 (01) :80-85

[26]

FIDLER MJ, 2008, J CLIN ONCOL, V26, pS432

[27] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[28] Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [J].

Greulich, H ;

Chen, TH ;

Feng, W ;

Jänne, PA ;

Alvarez, JV ;

Zappaterra, M ;

Bulmer, SE ;

Frank, DA ;

Hahn, WC ;

Sellers, WR ;

Meyerson, M .

PLOS MEDICINE, 2005, 2 (11) :1167-1176

[29] Molecular origins of cancer: Lung cancer [J].

Herbst, Roy S. ;

Heymach, John V. ;

Lippman, Scott M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1367-1380

[30] Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer [J].

Jaenne, Pasi A. ;

von Pawel, Joachim ;

Cohen, Roger B. ;

Crino, Lucio ;

Butts, Charles A. ;

Olson, Steven S. ;

Eiseman, Irene A. ;

Chiappori, Alberto A. ;

Yeap, Beow Y. ;

Lenehan, Peter F. ;

Dasse, Kathy ;

Sheeran, Meredith ;

Bonomi, Philip D. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3936-3944

← 1 2 3 4 5 6 7 8 9 →